Breast Cancer News and Research

Latest Breast Cancer News and Research

Genetic risk factor for colorectal and prostate cancer

A study led by researchers at the Keck School of Medicine of the University of Southern California (USC) has found that one of seven genetic risk factors previously identified as increasing the probability of developing prostate cancer also increases the probability of developing colorectal cancer.

9 Jul 2007

Breast enlargements in just over an hour!

Women in the UK could be getting breast enlargements in their lunch time as soon as 2008, reports Lisa Melton in Chemistry & Industry, the magazine of the Society of Chemical Industry.

9 Jul 2007

Common genetic risk factor for multiple cancers identified

9 Jul 2007

Trastuzumab and chemo improves survival in women with operable HER-2 positive breast cancer

A recent meta-analysis of five major breast cancer trials has confirmed that combination treatment with the antibody trastuzumab and chemotherapy improves survival in women with operable HER-2 positive breast cancer.

9 Jul 2007

OncoLife web-based cancer survivorhip care plan

A team of cancer specialists from OncoLink.org, the award-winning cancer Web-based resource of the Abramson Cancer Center of the University of Pennsylvania, has launched OncoLife, the first and only individualized plan-of-care based on the national Institute of Medicine's recommendations for adult cancer survivors.

4 Jul 2007

Harnessing the power of the immune system to fight cancer

Teaching a body's own immune system to seek out and destroy cancerous tumours represents a promising way to fight a disease that kills more than 70,000 Canadians a year.

4 Jul 2007

Biomira files NDA for novel inhibitor of hypoxia-inducible factor-1 alpha

Biomira Inc. has announced that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration for PX-478. PX-478 has been shown in preclinical studies to inhibit hypoxia-inducible factor (HIF)-1 alpha, a protein that controls the transcription of a number of genes whose products are important for tumor growth and survival.

4 Jul 2007

Genetic mutation that may alter response to cancer therapeutics found

Researchers from Eli Lilly & Company and the Phoenix-based Translational Genomics Research Institute (TGen) today announced finding a novel recurring mutation of the gene AKT1 in breast, colorectal and ovarian cancers.

4 Jul 2007

The next era of cancer treatment

Teaching a body's own immune system to seek out and destroy cancerous tumours represents a promising way to fight a disease that kills more than 70,000 Canadians a year.

4 Jul 2007

Discovery of method to identify how cancer evades the immune system

One of the fundamental traits of a tumor - how it avoids the immune system - might become its greatest vulnerability, according to researchers from the University of Southern California. Their findings, demonstrated in human breast and colorectal cancers, indicate that a technique for determining a tumor's "immune signature," could be useful for diagnosing and treating specific cancers.

3 Jul 2007

Dangers of permitting smoking in the workplace

Offering alarming new evidence on the dangers of permitting smoking in the workplace, scientists have found that nonsmoking restaurant and bar employees absorb a potent carcinogennot considered safe at any levelwhile working in places where they had to breathe tobacco smoke from customers and co-workers.

29 Jun 2007

Breast cancer survival runs in the family

The chances of developing breast cancer are to some extent inherited, but important new findings suggest survival also runs in the family.

29 Jun 2007

Support for chromosomal theory of cancer found in cancers' development of drug resistance

Thirty-six years into the war on cancer, scientists have not only failed to come up with a cure, but most of the newer drugs suffer from the same problems as those available in the pre-war days: serious toxicity, limited effectiveness and eventual resistance.

28 Jun 2007

Trial shows CERVARIX cervical cancer candidate vaccine effective

Results from an interim analysis of a Phase III study show that CERVARIX, the GlaxoSmithKline (GSK) cervical cancer candidate vaccine, provides up to 100 percent protection against advanced precancerous lesions caused by the most common types of human papillomavirus, types 16 and 18.

28 Jun 2007

Bayer and Onyx submit supplemental NDA for Nexavar

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals have announced that a Supplemental New Drug Application (sNDA) for Nexavar (sorafenib) tablets has been submitted to the U.S. Food and Drug Administration (FDA) for the treatment of patients with hepatocellular carcinoma (HCC), the most common form of liver cancer. Nexavar is currently approved in more than 50 countries for the treatment of advanced kidney cancer.

28 Jun 2007